Story perspectives

Grail Shares Jump 33% After FDA Posts Galleri Documents

By Drooid · Sep 22, 2026, 11:32 PM UTC · How we work

Summary

Story summary

Grail's shares rose 33% after the FDA posted documents suggesting a favorable view of its Galleri cancer test.
The FDA posted the documents on Monday, ahead of a Wednesday advisory committee meeting.
Investors had already been bidding up Grail’s stock in anticipation of the meeting.
FDA approval would likely enable Medicare and other insurers to reimburse the Galleri test.

1 of 1

Story summary

Grail's shares rose 33% after the FDA posted documents suggesting a favorable view of its Galleri cancer test.
The FDA posted the documents on Monday, ahead of a Wednesday advisory committee meeting.
Investors had already been bidding up Grail’s stock in anticipation of the meeting.
FDA approval would likely enable Medicare and other insurers to reimburse the Galleri test.